trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, SHR-A1921 / Jiangsu Hengrui Pharma
    A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_6678;    
    P2
    This molecular subtype-guided precision therapy for advanced salivary gland cancer showed promising results with acceptable toxicity. Clinical trial information: NCT05924256.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) -  Mar 21, 2024   
    P1,  N=101, Active, not recruiting, 
    Patients with radiotherapy-na Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, SHR-A1921 / Jiangsu Hengrui Pharma
    Enrollment change, Metastases:  A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) -  Mar 15, 2024   
    P2,  N=88, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 N=66 --> 88
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov) -  Nov 1, 2023   
    P2,  N=120, Recruiting, 
    Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, SHR-A1921 / Jiangsu Hengrui Pharma
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) -  Aug 2, 2023   
    P2,  N=66, Recruiting, 
    Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Trial primary completion date, Metastases:  A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  May 10, 2023   
    P1/2,  N=153, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Jan 2023 --> May 2023
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients (clinicaltrials.gov) -  Mar 21, 2023   
    P2,  N=61, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Nov 2028 --> Feb 2029 | Initiation date: Nov 2022 --> Mar 2023 | Trial primary completion date: Nov 2023 --> Feb 2024
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study (Section 45; Poster Board #7) -  Mar 14, 2023 - Abstract #AACR2023AACR_5998;    
    Subgroup analyses of ORRNo. of prior treatment lines in metastatic setting in all pts (N=250)HER2 positive BC (N=108)HER2-low BC (N=77)Other tumor types (N=65)?381.8% (45/55)58.7% (27/46)36.7% (18/49)>381.1% (43/53)51.6% (16/31)31.3% (5/16)Prior anti-HER2 therapies in pts with BC (N=185)*HER2 positive BC (N=108)HER2-low BC (N=77)All BC (N=185)Any82.2% (88/107, 73.7-89.0)68.8% (11/16, 41.3-89.0)80.5% (99/123, 72.4-87.1)Trastuzumab81.9% (86/105, 73.2-88.7)75.0% (9/12, 42.8-94.5)81.2% (95/117, 72.9-87.8)Pertuzumab83.0% (39/47, 69.2-92.4)100% (5/5, 47.8-100)84.6% (44/52, 71.9-93.1)Pyrotinib86.9% (53/61, 75.8-94.1)71.4% (5/7, 29.0-96.3)85.3% (58/68, 74.6-92.7)Lapatinib80.0% (28/35, 63.1-91.6)100% (1/1, 2.5-100)80.6% (29/36, 64.0-91.8)T-DM182.4% (14/17, 56.6-96.2)100% (3/3, 29.2-100)85.0% (17/20, 62.1-96.8)Other HER2-ADC (except T-DM1)**60.0% (9/15, 32.3-83.7)50.0% (2/4, 6.8-93.2)57.9% (11/19, 33.5-79.8)ORR in pts with tumor types other than BC (N=65)HER2 IHC3+ or IHC2+/ISH+ (N=36)HER2 IHC2+/ISH- or IHC1+ or unknown (N=29)All other tumor types (N=65)% (n/N)38.9% (14/36)31.0% (9/29)35.4% (23/65)ORR was shown as % (n/N, 95% CI) or % (n/N).
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles (Section 35; Poster Board #23) -  Mar 14, 2023 - Abstract #AACR2023AACR_2087;    
    P1/2, P2,
    Here we presented a potential best-in-class HER2-directed ADC, SHR-A1811, which was composed of trastuzumab, a stable and cleavable linker, and a novel topoisomerase I inhibitor payload (SHR9265)...In summary, with a highly permeable payload, optimized DAR, great potency and better clinical safety profiles, SHR-A1811 has demonstrated the best-in-class potential. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC (NCT05424835, NCT05482568, NCT04818333, NCT05349409).
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
    New P2 trial:  FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov) -  Mar 1, 2023   
    P2,  N=120, Not yet recruiting, 
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
    Enrollment open, Combination therapy:  A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (clinicaltrials.gov) -  Feb 21, 2023   
    P2,  N=402, Recruiting, 
    Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC (NCT05424835, NCT05482568, NCT04818333, NCT05349409). Not yet recruiting --> Recruiting
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Enrollment open, Combination therapy, Metastases:  A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers (clinicaltrials.gov) -  Jun 30, 2022   
    P2,  N=212, Enrolling by invitation, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) -  May 18, 2022   
    P1,  N=114, Recruiting, 
    Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Jun 2023